Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing ...

The S&P500 (SP500)closed in the red, after the week witnessed muted inflation data, a court striking down President Trump's ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The S&P 500 (^GSPC) logged its best May since 1990 and its best month since Nov. 2023, rising over 6%, while the Dow (^DJI) ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

STORY: U.S. stocks ended a choppy session mixed on Friday, with the Dow up marginally, the S&P 500 flat and the Nasdaq down ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Key Takeaways U.S. equities were lower at midday on concerns about where the U.S.-China trade war is heading.A late-stage trial for a COPD drug developed by Regeneron Pharmaceuticals and Sanofi missed ...